Editorial: Physostigmine: value in treatment of central toxic effects of anti-cholinergic drugs.
D000639:Amitriptyline / Q000009:adverse effects; D001590:Benztropine / Q000009:adverse effects; D001921:Brain / Q000187:drug effects*; D004316:Doxepin / Q000009:adverse effects; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D007273:Injections, Intramuscular; D001523:Mental Disorders / Q000188:drug therapy; D010276:Parasympatholytics / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D010830:Physostigmine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D013881:Thioridazine / Q000009:adverse effects
D010276:Parasympatholytics; D004316:Doxepin; D000639:Amitriptyline; D001590:Benztropine; D010830:Physostigmine; D006220:Haloperidol; D013881:Thioridazine